https://www.selleckchem.com/pr....oducts/meclofenamate
Fenfluramine has been shown to provide clinically meaningful and statistically significant reductions in convulsive seizure frequency in children and adolescents (aged 2-18years) with Dravet syndrome in two randomized, placebo-controlled clinical trials. The objective of this analysis was to assess longer-term safety and efficacy of fenfluramine in patients who completed one of the double-blind studies and entered an open-label extension (OLE) study. Patients enrolling in the OLE study initiated fenfluramine at 0.2mg/kg/d r
Like
Comment
Share
